Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors

[1]  T. Wilt,et al.  Immunotherapy for advanced renal cell cancer. , 2015, The Cochrane database of systematic reviews.

[2]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[3]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[4]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[5]  S. Strand,et al.  Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells. , 2006, Cancer research.

[6]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[7]  N. Ueno,et al.  The Second International Meeting on Allogeneic Transplantation in Solid Tumors , 2006, Bone Marrow Transplantation.

[8]  Mark Ende,et al.  Hematopoietic stem-cell transplantation. , 2006, The New England journal of medicine.

[9]  F. Re,et al.  Killer cell Ig‐like receptors ligand‐mismatched, alloreactive natural killer cells lyse primary solid tumors , 2006, Cancer.

[10]  P. Pedrazzoli,et al.  Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  E. Small,et al.  Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[12]  M. Aglietta,et al.  Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD. , 2006, Blood.

[13]  G. Parmiani.  Tumor-infiltrating T cells--friend or foe of neoplastic cells? , 2005, The New England journal of medicine.

[14]  J. Esteve,et al.  Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) , 2005, Leukemia.

[15]  M. Sormani,et al.  Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation , 2005, Cancer.

[16]  A. Barrett,et al.  Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. , 2005, Blood.

[17]  A. Ballestrero,et al.  Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer , 2005, The Lancet.

[18]  R. Simon,et al.  Prognostic Factors for Survival , 2005 .

[19]  K. Ohtomo,et al.  Graft-versus-Tumor Effect Against Advanced Pancreatic Cancer after Allogeneic Reduced-Intensity Stem Cell Transplantation , 2005, Transplantation.

[20]  S. Rosenberg,et al.  Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  A. Bertuzzi,et al.  Lack of activity of allogeneic stem cell transplantation with reduced-intensity conditioning regimens in advanced sarcomas , 2005, Bone Marrow Transplantation.

[22]  S. Steinberg,et al.  Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  B. Dörken,et al.  Nonmyeloablative stem cell transplantation in metastatic renal cell carcinoma: delayed graft-versus-tumor effect is associated with chimerism conversion but transplantation has high toxicity , 2004, Bone Marrow Transplantation.

[24]  Armando Santoro,et al.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.

[25]  E. Pujade-Lauraine,et al.  Phase III randomized trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients (pts) with advanced ovarian cancer (AOC): 5-year follow-up of a GINECO/FNCLCC/SFGM-TC study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. P. McCoy,et al.  Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. , 2004, Blood.

[27]  M. Kami,et al.  Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma: single institution experience with a minimum 1-year follow-up. , 2004, Experimental hematology.

[28]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[29]  H. Sakamaki,et al.  Nonmyeloablative Allogeneic Stem Cell Transplantation for Patients With Unresectable Pancreatic Cancer , 2004, Pancreas.

[30]  J. Lam,et al.  Generation of Kidney Cancer-Specific Antitumor Immune Responses Using Peripheral Blood Monocytes Transduced With a Recombinant Adenovirus Encoding Carbonic Anhydrase 9 , 2004, Clinical Cancer Research.

[31]  S. Slavin,et al.  Nonmyeloablative stem cell transplantation: reduced-intensity conditioning for cancer immunotherapy--from bench to patient bedside. , 2004, Seminars in oncology.

[32]  D. Blaise,et al.  Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. , 2004, Blood.

[33]  Jonathan W. Yewdell,et al.  Immune recognition of a human renal cancer antigen through post-translational protein splicing , 2004, Nature.

[34]  G. Hortobagyi,et al.  Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. , 2003, Blood.

[35]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[36]  D. Blaise,et al.  Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. , 2003, Blood.

[37]  S. Bearman.  Reduced-intensity allogeneic stem cell transplantation. , 2003, Current hematology reports.

[38]  H. Sakamaki,et al.  Regression of an unresectable pancreatic tumor following nonmyeloablative allogeneic peripheral-blood stem-cell transplantation , 2003, Bone Marrow Transplantation.

[39]  A. Hagenbeek,et al.  Safety of retroviral gene marking with a truncated NGF receptor , 2003, Nature Medicine.

[40]  Els Goulmy,et al.  Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[41]  R. Storb,et al.  Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissio , 2003, Blood.

[42]  P. Pisa,et al.  Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma , 2003, Bone Marrow Transplantation.

[43]  H. Hosoi,et al.  Regression of Refractory Rhabdomyosarcoma After Allogeneic Stem-Cell Transplantation , 2003, Pediatric hematology and oncology.

[44]  E. Leifer,et al.  Non-myeloablative allogeneic stem cell transplantation (NST) for metastatic melanoma: nondurable chemotherapy responses without clinically meaningful graft-vs-tumor (GVT) effects. , 2002 .

[45]  M. Wilke,et al.  The Hematopoietic System–specific Minor Histocompatibility Antigen HA-1 Shows Aberrant Expression in Epithelial Cancer Cells , 2002, The Journal of experimental medicine.

[46]  D. Blaise,et al.  Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: results of five patients , 2002, Bone Marrow Transplantation.

[47]  C. Voena,et al.  Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. , 2002, Blood.

[48]  P. Pedrazzoli,et al.  Allogeneic blood stem cell transplantation after a reduced‐intensity, preparative regimen , 2002, Cancer.

[49]  T. Zimmerman,et al.  Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  D. Rizzieri,et al.  Successful allogeneic engraftment of mismatched unrelated cord blood following a nonmyeloablative preparative regimen. , 2001, Blood.

[51]  R. Figlin,et al.  Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor. , 2001, Cancer research.

[52]  R. Kridel,et al.  An Alternative Open Reading Frame of the Human Macrophage Colony-Stimulating Factor Gene Is Independently Translated and Codes for an Antigenic Peptide of 14 Amino Acids Recognized by Tumor-Infiltrating Cd8 T Lymphocytes , 2001, The Journal of experimental medicine.

[53]  Steven A. Rosenberg,et al.  Progress in human tumour immunology and immunotherapy , 2001, Nature.

[54]  S. Slavin,et al.  Cell Therapy With Preimmunized Effector Cells Mismatched for Minor Histocompatible Antigens in the Treatment of a Murine Mammary Carcinoma , 2001, Journal of immunotherapy : official journal of the Society for Biological Therapy.

[55]  W. Linehan,et al.  Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. , 2000, The New England journal of medicine.

[56]  S. Rosenberg,et al.  A new era for cancer immunotherapy based on the genes that encode cancer antigens. , 1999, Immunity.

[57]  E. Angevin,et al.  A hsp70-2 mutation recognized by CTL on a human renal cell carcinoma. , 1999, Journal of immunology.

[58]  A. Diab,et al.  Allogeneic cell therapy for a murine mammary carcinoma. , 1998, Cancer research.

[59]  S. Steinberg,et al.  Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. , 1998, Annals of surgery.

[60]  N. Ueno,et al.  Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  D. Schendel,et al.  Human renal cell carcinoma antigen-specific CTLs: antigen-driven selection and long-term persistence in vivo. , 1998, Cancer research.

[62]  E. Warren,et al.  Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. , 1998, Blood.

[63]  G. Hortobagyi,et al.  Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  D. V. Von Hoff,et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  M. Canis,et al.  High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  Y. Moshel,et al.  Induction of graft vs. tumor effect in a murine model of mammary adenocarcinoma , 1997, International journal of cancer.

[67]  D. Porter,et al.  Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation. , 1996, Bone marrow transplantation.

[68]  D. Carbone,et al.  Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells , 1996, Nature Medicine.

[69]  C. Marth,et al.  Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. , 1996, Blood.

[70]  F. Brasseur,et al.  A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma , 1996, The Journal of experimental medicine.

[71]  A Ferrant,et al.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. , 1995, Blood.

[72]  S. Mackinnon,et al.  Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. , 1995, Blood.

[73]  K. Sakaguchi,et al.  Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[74]  S. Rosenberg,et al.  Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[75]  P. Selby.  High-dose chemotherapy. , 1987, Chemioterapia : international journal of the Mediterranean Society of Chemotherapy.

[76]  S. Rosenberg,et al.  A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. , 1986, Science.

[77]  S. Slavin,et al.  Anti-tumor effects of allogeneic bone marrow transplantation in (NZB X NZW)F1 hybrids with spontaneous lymphosarcoma. , 1984, Journal of immunology.

[78]  G. Deichman,et al.  Inhibition of experimental and spontaneous lung metastases of highly metastatic syrian hamster sarcoma cells by non‐activated bone marrow and peritoneal exudate cells , 1983, International journal of cancer.

[79]  B. Sandmaier,et al.  Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: current perspectives. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[80]  J. Patard,et al.  A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma , 2007, Immunogenetics.

[81]  S. Slavin,et al.  Use of matched or mismatched rIL-2 activated donor lymphocytes positively selected for CD56+ for immunotherapy of resistant leukemia after allogeneic stem cell transplantation. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  F. Baron,et al.  Non-myeloablative stem cell transplantation with low-dose total body irradiation and fludarabine for metastatic renal cell carcinoma. , 2003, Haematologica.

[83]  A. Carella,et al.  Combined use of autografting and non-myeloablative allografting for the treatment of hematologic malignancies and metastatic breast cancer. , 2002, Cancer treatment and research.

[84]  L Davies,et al.  Bone marrow transplant. , 1985, Nursing times.

[85]  M. Karno,et al.  Renal cell carcinoma. , 1956, Bulletin. Tufts-New England Medical Center.